Q4 FY2024 · ended Dec 31, 2024 · Revenue $725,403, -54.0% YoY · Filed Apr 15, 2026
Petros Pharmaceuticals, Inc. (PTPI) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$725,403
-54.0% vs prior quarter
Net income
$-955,625
-117.6% vs year-ago quarter
Operating cash flow
$-863,855
+71.3% vs year-ago quarter
Free cash flow
$-790,384
EPS
$-0.30
+75.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
42.37M
+0.0% vs year-ago quarter
Net cash
$1.58M
Q4 FY2024
Operating margin
-79.6%
Q4 FY2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PTPI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1815903
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$988,501 | -$1.0M | -$391,486 | -$990,737 | -$1.8M |
| Net income | -$955,625 | -$987,036 | -$336,506 | -$922,723 | $5.4M |
| Diluted EPS | -$0.30 | -$0.03 | -$0.01 | -$0.03 | -$1.20 |
| Operating cash flow | -$863,855 | -$784,272 | -$933,544 | -$1.1M | -$3.0M |
| Total assets | $3.5M | $4.4M | $5.2M | $6.1M | $7.4M |
| Total liabilities | $2.8M | $2.6M | $2.3M | $2.8M | $2.9M |
| Stockholders' equity | $700,894 | $1.8M | $2.9M | $3.4M | $4.4M |
| Cash and investments | $3.5M | $4.4M | $5.1M | $6.1M | $7.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bankruptcy, Officer or director change
|
Sep 30, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 18, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 5, 2026 | Jun 5, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 15, 2026 | Dec 31, 2025 |
All 257 Petros Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.